Immunocore
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies.
Immunocore has raised €252M across 2 funding rounds from 2 investors, most recently a Debt round in Feb 2021. Based in Abingdon, UK; founded 2008; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€252M
€251,652,887
Funding rounds
2
Investors
2
distinct backers
Active since
2021-01
latest 2021-02
Funding by year
EUR raised per yearImmunocore — funding by year — interactive chart.
Data table
| Immunocore — funding by year | |
|---|---|
| 2021 | €252M |
Signals
High confidenceRaise-next likelihood9
base rate 45% for Debt
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▼ Old (18y) — past typical exit age
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-02-05 | Debt | €190M | Oxford Finance LLC | View deal → |
| 2021-01-13 | Series C | €62M | BlackRock | View deal → |